In Rwanda, frequent mutations in the pfdhfr and pfdhps genes of Plasmodium falciparum have suggested intense sulfadoxine–pyrimethamine resistance.
The main objective of this investigation was whether the combination therapy of sulfadoxine pyrimethamine (SP) plus artesunate (AS) protects against the spread of resistance to SP in malaria-endemic south-eastern Iran.
We examined the frequency of Plasmodium falciparum chloroquine transporter (pfcrt; codons 72–76) haplotypes in Sri Lanka in 1996–1998 and 2004–2006 using a high-resolution melting assay.
Thus, we evaluated the influence of pfcrt and pfmdr1 polymorphisms on in vitro chloroquine sensitivity in 89 adapted isolates of P. falciparum from Thailand. We found that 87 of 89 isolates contained the CVIET haplotype of the pfcrt gene.
We present three cases of unusual and complicated malaria caused by Plasmodium vivax.
The malaria parasite's molecular responses to PN and CQ treatment are similar in terms of the genes and pathways affected.
In the current study, ex vivo FQ activity was tested in multidrug-resistant P. falciparum and P. vivax field isolates using a schizont maturation assay.
Ten-fold lower clinical doses of tafenoquine than used in prior studies may be effective against P. vivax hypnozoites if the drug is deployed in combination with effective blood-schizonticidal drugs.
In Jalpaiguri District the overall failure rate of CQ was 61% and of SP 14%, which was well above the WHO recommended cut-off threshold level (10%) for change of drug policy.
The pfATPase6 gene is highly polymorphic with D639G appearing to be fixed in Ghanaian isolates.